公开(公告)号：US20240336638A1

公开(公告)日：2024-10-10

申请号：US18571763

申请日：2022-06-28

申请人： Guoqin ZHUGE ,  Xiaoqin LI

发明人： Xiaoqin LI ,  Jianfang CHEN

IPC分类号： C07F7/18 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

CPC分类号： C07F7/1804 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

摘要： An imidazole compound as shown in formula I or a pharmaceutically acceptable salt and an intermediate thereof. The imidazole compound as shown in formula I can significantly inhibit AA-induced platelet aggregation, improves MCAO/R-induced rat cerebral ischemia injury, has excellent metabolic stability, and can improve the distribution of a drug within the brain tissue, such that the pharmacodynamic activity of the imidazole compound in treatment of dyskinesia associated with acute thrombotic cerebral infarction and cerebral infarction is improved.